Cationic Thiolated Poly(aspartamide) Polymer as a Potential Excipient for Artificial Tear Formulations by Budai-Szűcs, Mária et al.
Research Article
Cationic Thiolated Poly(aspartamide) Polymer as
a Potential Excipient for Artificial Tear Formulations
Mária Budai-Sz4cs,1 Gabriella Horvát,1 Barnabás Áron Szilágyi,2
Benjámin Gyarmati,2 András Szilágyi,2 Szilvia Berkó,1 Piroska Szabó-Révész,1
Giuseppina Sandri,3 Maria Cristina Bonferoni,3 Carla Caramella,3 Judit Soós,4
Andrea Facskó,4 and Erzsébet Csányi1
1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Szeged, Eo¨tvo¨s utca 6, Szeged 6720, Hungary
2Soft Matters Group, Department of Physical Chemistry and Materials Science,
Budapest University of Technology and Economics, Budafoki u´t 8, Budapest 1111, Hungary
3Department of Drug Sciences, Faculty of Pharmacy, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
4Department of Ophthalmology, Faculty of Medicine, University of Szeged, Kora´nyi fasor 10-11, Szeged 6720, Hungary
Correspondence should be addressed to Erzse´bet Csa´nyi; csanyi@pharm.u-szeged.hu
Received 16 December 2015; Revised 15 April 2016; Accepted 26 April 2016
Academic Editor: Chuanqing Ding
Copyright © 2016 Ma´ria Budai-Szu˝cs et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Dry eye disease is a relatively common ocular problem, which causes eye discomfort and visual disorders leading to a decrease in
the quality of life. The aim of this study was to find a possible excipient for eye drop formulations, which is able to stabilize the tear
film. A cationic thiolated polyaspartamide polymer, poly[(N-mercaptoethylaspartamide)-co-(N-(N󸀠,N󸀠-dimethylaminoethyl)as-
partamide)] (ThioPASP-DME), was used as a potential vehicle. Besides satisfying the basic requirements, the chemical structure of
ThioPASP-DME is similar to those of ocular mucins as it is a protein-like polymer bearing a considerable number of thiol groups.
The solution of the polymer is therefore able to mimic the physiological properties of the mucins and it can interact with the mucus
layer via disulphide bond formation.The resultant mucoadhesion provides a prolonged residence time and ensures protective effect
for the corneal/conjunctival epithelium.ThioPASP-DME also has an antioxidant effect due to the presence of the thiol groups. The
applicability of ThioPASP-DME as a potential excipient in eye drops was determined by means of ocular compatibility tests and
through examinations of the interactions with themucosal surface.The results indicate thatThioPASP-DME can serve as a potential
eye drop excipient for the therapy of dry eye disease.
1. Introduction
Dry eye disease (DED) has been reported to afflict 7–33%
of the population, thereby reducing their quality of life. For
normal vision, continuous moistening of the ocular surface
is needed. Important roles are played in this by a sufficient
quality of tears, maintenance of the normal composition of
the tear film, normal lid closure, and regular blinking [1, 2].
If equilibrium is lost, the DED can occur, resulting in eye
discomfort and visual disturbance [2, 3].
DED is accompanied by changes in mucin distribution
and glycosylation, a dysfunction of MUC4 and MUC5AC
and a high calcium level [4]. The mucins act as a lubricant
during blinking, stabilize the preocular tear film to prevent
desiccation of the epithelium, and form a barrier against
pathogen penetrance [5]. Intracellular calcium is responsible
for cationic shielding to keep negatively charged mucins
condensed and packed within the granules of goblet cells.
In the event of enhanced calcium release, the granules swell,
become detached from the cell surface, form large aggregates,
and diffuse onto the epithelial surface. This leads to a lower
degree of hydration of the mucus coverage, which contains
dry spots, resulting in decreased tear film stability [4].
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Figure 1: Synthesis of cationic ThioPASP-DME polymers.
One way to stabilize the tear film in cases of DED is to
use liquid thiolated polymer formulations, whose structures
are similar to those of ocular mucins, as they are protein-like
polymers bearing a considerable number of thiol groups.The
solutions of such polymers are therefore able to mimic the
physiological properties of mucins, such as tear film stabi-
lization. The formation of disulphide bonds with the mucus
layer leads to strong mucoadhesion, which may be further
strengthened by the formation of ionic bonds between the
cationic groups of the excipient and the anionic groups of the
mucins.The strong adhesion promotes a prolonged residence
time and a protective effect for the corneal/conjunctival
epithelium. Liquid formulations also serve as lubricants,
prolonging the breakup time of the tear film. Moreover,
thiolated polymers have antioxidant and radical scavenging
properties and can therefore be useful excipients in artificial
tear formulations for the therapy of DED [4, 6].
We earlier described thiolated poly(aspartic acid)
(ThioPASP) polymers, which are biocompatible [7, 8], in situ
gelling, and potential ophthalmic vehicles [9, 10]. The aims
of the present study were to synthetize and characterize a
cationic thiolated poly(aspartamide) bearing both cationic
tertiary amine and redox-responsive thiol pendant groups as
a potential mucoadhesive and tear film-stabilizing excipient
in the therapy of DED. Ocular compatibility tests were
performed to determine its applicability as a potential excip-
ient in eye drops.
2. Materials and Methods
2.1. Materials. For the synthesis of the polymers, L-aspartic
acid (Merck, extra pure), phosphoric acid (Sigma Aldrich,
99%), cysteamine (Acros Organics, 95%), N,N-dimethyleth-
ylenediamine (Sigma Aldrich, 95%), ethyl acetate (Reanal
Hungary, a.r.), acetone (Reanal Hungary, a.r.), and N,N-
dimethylformamide (DMF)were usedwithout further purifi-
cation. To mimic the oxidative effect on the ocular surface,
20%w/w 1M NaBrO
3
was used as model oxidant in the
formulations. A phosphate-buffered saline (PBS) solution
of pH = 7.4 was prepared by dissolving 8 g dm−3 NaCl,
0.2 g dm−3 KCl, 1.44 g dm−3Na
2
HPO
4
⋅2H
2
O, and 0.12 g dm−3
KH
2
PO
4
in distilled water, with the pH being adjusted with
0.1MHCl. Lacrimal fluid of pH= 7.4was prepared by dissolv-
ing 2.2 g dm−3 NaHCO
3
, 6.26 g dm−3 NaCl, 1.79 g dm−3 KCl,
96.4mg dm− MgCl
2
⋅6H
2
O, and 73.5mg dm−3 CaCl
2
⋅H
2
O
in distilled water, with the pH being adjusted with 1M
HCl. Mucin (porcine gastric mucin type II) was purchased
from Sigma Aldrich. Mucin dispersions were prepared with
simulated lacrimal fluid and stirred for 8 h. As reference
system eye drop formulation from the market was used,
consisting of dextran, hypromellose, benzalkonium chloride,
EDTA, KCl, NaCl, and water for injection, with the pH being
adjusted with HCl and NaOH. Sodium hyaluronate (HA)
(MW: 4350 kDa) was purchased from RichterGedeon Ltd.
(Budapest, Hungary).
2.2. Synthesis of Cationic ThioPASP-DME Polymers. The
precursor polymer of cationic ThioPASP, polysuccinimide
(PSI), was synthesized by the thermal polycondensation of L-
aspartic acid in a solvent-free reaction at high temperature
and reduced pressure. PSI and cysteamine were dissolved
in DMF under a nitrogen atmosphere and the solution was
stirred for 72 h at room temperature. An excess of N,N-
dimethylethylenediamine was then added and the mixture
was stirred for another 24 h under a nitrogen atmosphere.
The polymer was precipitated in an excess of ethyl acetate
and washed with ethyl acetate and acetone to yield the free
base of poly[(N-mercaptoethylaspartamide)-co-(N-(N󸀠,N󸀠-
dimethylaminoethyl)aspartamide)] (ThioPASP-DME). The
polymers are abbreviated as ThioPASP-DME 𝑋, where 𝑋 is
the percentage molar ratio of the N-mercaptoethyl aspar-
tamide to the total number of repeating units (Figure 1).
2.3. Ocular Compatibility Tests. Osmolality and pH were
measured in 10%w/w aqueous solutions of ThioPASP-
DME. Osmolality measurements based on the freezing point
depression of a solution were carried out with an automatic
osmometer (Knauer Semimicro Osmometer, Germany) in
3 parallels. 150𝜇L of the solution in a test tube was placed
into the instrument, and the sample was overcooled to
a temperature lower than its freezing point. Mixing was
next applied, which promoted crystallization of the sample.
During the crystallization, the temperature automatically
rose to the freezing point of the sample and remained at that
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temperature for a time. The osmolality (in mOsmol L−1) of
the sample was calculated from the freezing point depression.
The pH of ThioPASP-DME solutions prepared with dis-
tilled water was determinedwith a pHmeter (Testo 206-pH2,
UK) [10].
2.4. Optical Tests. Optical tests were performed by the
measurement of transmittancewith aUV-spectrophotometer
(Thermo Scientific Evolution 201 UV-Visible Spectropho-
tometer, Thermo Fischer Scientific, Shanghai, China) in the
wavelength range 200–800 nm. In our investigations, the
thickness of the samples was 10mm. The transmittance in
aqueous solutions of ThioPASP-DME was determined at
10%w/w.
The refractive index of the same solution was measured
with an Abbe refractometer [10].
2.5. Wettability of Ocular Surfaces. The wettability of ocu-
lar surfaces with cationic ThioPASP formulations (10%w/w
ThioPASP-DME polymers in PBS) was studied with an OCA
Contact Angle System (Dataphysics OCA 20, Dataphysics
Inc., GmbH, Germany). Microscopic slides were covered
with 20𝜇L cm−2 5%w/w mucin dispersion in PBS and dried
at room temperature for 24 h to model the ocular surface.
Drops of ThioPASP-DME solutions were deposited on the
surfaces.The degree of wetting was determined bymeasuring
the contact angle by drop shape analysis. If the contact
angle of the drops is <90∘, the applied system will probably
spread easily on the ocular surface, which can promote the
interactions between the mucus layer and the formulation.
2.6. Rheology. The effect of the oxidative agent on the
polymer solutions and the interaction between the polymer
solution and the ocular mucin were investigated by rheology.
The rheological properties were studied with a Physica
MCR101 rheometer (Anton Paar, Austria). The measuring
device was cone and plate type (the diameter was 25mm,
the gap height in the middle of the cone was 0.046mm, and
the cone angle was 1∘). ThioPASP-DME was dissolved in PBS
and the gelation test was initiated by the addition of model
oxidant. For the investigation of the interaction between the
polymer and the ocular mucin, the polymer was mixed with
a mucin dispersion in PBS and in the presence of 20%w/w
model oxidant (the final mucin concentration was 5%w/w,
while the final polymer concentration was 10%w/w). As
blankmeasurement, the polymer solutionwithoutmucinwas
measured. The structural changes in the formulation were
characterized by frequency sweep tests. The oxidative effect
on the eye can induce gelation, and the interactions between
ThioPASP-DME and mucin can also result in structural
changes; the storage modulus (𝐺󸀠) was therefore measured
in two different rheological tests. 𝐺󸀠 indicates the gel state
and can also provide information on the strength of the
interactions. The higher the value of 𝐺󸀠, the stronger the
gel structure formed. In the first rheological test, 𝐺󸀠 was
plotted for 20min after the addition of model oxidant,
using a strain of 1% and an angular frequency of 0.1 s−1 at
25∘C. This test follows the possible gelation process. In the
second rheological test, 𝐺󸀠 was determined over the angular
frequency range from 0.1 to 100 s−1, at a strain of 1% and at
25∘C.This test provides information concerning the structure
and the strength of the interactions [9].
2.7. Tensile Test. Tensile test also provides information on the
interfacial interaction of the polymer and the ocular surface.
Measurements were performed with a TA-XT Plus (Texture
analyser (ENCO, Spinea, I)) instrument equipped with a 1 kg
load cell and a cylinder probe with a diameter of 1 cm. The
force and work needed to separate the polymer solution from
the ocular surface are measured, which can characterize the
strength of the interaction. Three different test conditions
were used: the ocular surface was modelled (1) with 50 𝜇L of
an 8%w/w mucin dispersion made with simulated lacrimal
fluid (pH = 7.4) on a filter paper (in vitro condition), (2)
with excised porcine conjunctiva (ex vivo condition), and (3)
with simulated lacrimal fluid on a filter paper (as a blank
measurement).
The porcine conjunctiva was obtained from a slaughter-
house, freshly detached from the connective tissue and stored
at −20∘C until the measurement. 10 parallel measurements
were carried out. Test conditions were as follows: 20𝜇L of the
ThioPASP-DME (containing 20%w/w oxidant and 10%w/w
polymer) and HA (0.5 and 1.0%w/w) solutions were attached
to a cylinder probe and placed in contact with the test
substrates (in vitro, ex vivo, and blank). A 2500mN preload
was used for 3min to establish intimate contact between the
sample and the test surface. The cylinder probe was then
moved upwards to separate the sample from the substrate at
a prefixed speed of 2.5mmmin−1. The work of adhesion (A,
mN⋅mm) was calculated as the area under the force versus
displacement curve (AUC) [9].
2.8. Statistical Analysis. The results were evaluated and anal-
ysed statistically with GraphPad Prism software (version 5).
One-way and two-way ANOVA (with Bonferroni posttests)
analysis were applied [11]. The values are expressed as means
± standard deviation (SD). A level of 𝑝 ≤ 0.05 was taken as
significant, 𝑝 ≤ 0.01 as very significant, and 𝑝 ≤ 0.001 as
highly significant.
3. Results
3.1. Ocular Compatibility Tests. During ocular drug delivery
formulation, several excipients are usedwhich can change the
physical and physiological properties of the ocular surface
and the stability of the tear film [4, 12, 13]. The osmolality
and the pH of the ThioPASP-DME solutions were therefore
measured to determine the physicochemical properties of the
solutions. The results are presented in Table 1.
Aqueous solutions of ThioPASP-DME polymers showed
strong hypoosmolality (<100mOsmol L−1), while the refer-
ence system was close to isotonic (301.4mOsmol L−1). The
solutions were alkaline (pH> 7). In order tomodify the pH of
the polymer solution close to that of the tear film (pH = 7.4),
the synthesis was extended with a neutralization step. As a
result, the pH of this polymer solution was approximately the
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Table 1: Osmolality and pH of aqueous ThioPASP-DME solutions
(10%w/w).
ThioPASP-DME
degree of modification
(% 𝑛/𝑛)
Osmolality (mOsm/L) in water
Mean ± SD pH
10 87 ± 0 8.79
10∗ 183.67 ± 1.25 6.07
20 90 ± 2.94 8.80
30 89.67 ± 0.47 8.77
Reference 282 ± 2.45 6.65
∗Neutralized with HCl.
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Figure 2: Transmittance of ThioPASP-DME solutions.
physiological pH and that of the reference system (pH=6.07),
while the osmolality increased but remained hypoosmotic
(<200mOsmol L−1).
3.2. Optical Tests. Transmittance spectra of 10%w/w Thio-
PASP-DME solutions were determined to study the effects
of the solutions on the vision. The transmittance curves are
depicted in Figure 2.
The ThioPASP-DME solutions are not colourless but
slightly yellow, though the transmittance is high over almost
the whole range of the visible spectrum. There was no
significant effect of the degree of modification (composition)
of the ThioPASP-DME. Interestingly, the polymer solutions
exhibited a noteworthy UV cut-off at 350 nm; this behaviour
can be favourable in the event of eyes exposed to heavy UV
radiation.
The refractive indices of the ThioPASP−DME 10, 20, and
30 and the reference solutions were 1.3483, 1.3491, 1.3499, and
1.3350, respectively.
3.3. Wettability of the Ocular Surface. As it is intended to
use the ThioPASP-DME solutions in liquid eye drops, their
spreading on the ocular surface is an important aspect. In
our tests, the ocular surface was modelled with a microscope
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Figure 3: Contact angles of ThioPASP-DME solutions.
slide covered with a mucin dispersion.Themeasured contact
angles are to be seen in Figure 3.
The results indicate that the tested polymer compositions
provide favourable wetting conditions on the model surface,
because the contact angle is <90∘.
3.3.1. Rheology. The ThioPASP polymer solutions exhibited
in situ gelling [9]; the gelation ability of ThioPASP-DME
solutions was also tested. In the in vitro tests, in vivo factors
that affected the gelling properties were applied, such as
the model oxidant (as oxidative stress) and mucin (as a
physiological component of tear film). The gelation (storage
modulus (𝐺󸀠)) was first determined with and without mucin
in the presence of the oxidant.
No gelation was observed in the case of ThioPASP-
DME solutions. The 𝐺󸀠 values did not increase during the
examination time, which was in contrast with findings in our
previouswork, inwhich solutions ofThioPASP demonstrated
abrupt increases in 𝐺󸀠 within a few minutes. Even the
addition of mucin did not induce gelation in the case of
ThioPASP-DME.
Frequency sweep tests were performed with the aim of
determining any synergetic interaction between the Thio-
PASP-DME and the mucin (Figure 4). This method is based
on the determination of synergistic increases in rheological
parameters (𝐺󸀠) after the sample is mixed with a mucin
dispersion. The increase in 𝐺󸀠 is caused by chemical and
physical bond formation between themucin and the polymer
chains [9, 14–16].
A minor increase in 𝐺󸀠 was observed in the presence
of mucin for the lower degrees of modification, indicating
the interaction of the polymer and the mucin. The modulus
depended strongly on the angular frequency for the same
compositions without mucin and the frequency dependence
was slightly reduced in the presence of mucin, suggesting
the formation of a weak network. These differences were not
observed for the highest degree of modification (ThioPASP-
DME 30), where a rather frequency-independent 𝐺󸀠 was
observed both with and without mucin.
Journal of Ophthalmology 5
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Figure 4: Frequency sweep tests of (a)ThioPASP-DME 10, (b)ThioPASP-DME20, and (c)ThioPASP-DME30with (filled symbols) orwithout
(open symbols) mucin.
3.3.2. Tensile Test. Force was measured as a function of
displacement during tensile tests. The adhesive force (the
maximum in the curve) and the work of adhesion (the AUC)
were calculated [17]. The possible adhesion of ThioPASP-
DME solutions to the ocular surface was determined through
contacts with lacrimal fluid (blank), mucin dispersion (in
vitro), and porcine eye conjunctiva (ex vivo). The adhesive
force (𝐹) and the work of adhesion (𝐴) are shown in Figure 5.
Comparison of the blank with the in vitro and ex vivo
results revealed significant increases in F and A (Figure 5),
reflecting the interactions of the ThioPASP-DME polymer
with the model surfaces. The highest values were observed
in the case of the excised porcine conjunctiva, suggesting
that the polymer interacts not merely with the mucin, but
also with the other components of the ocular surface. The
adhesive force and the work of adhesion values did not vary
appreciably with the composition, but the substrate applied
during the measurements affected these values strongly, as
discussed below.
The mucoadhesivity of the new polymers was compared
with that of hyaluronic acid solutions. HA as viscosity
enhancing agent has been investigated for years as an
active component of formulations applied in DED. Sodium
hyaluronate increases the residence time and the precorneal
tear film stability and the corneal wettability. It also decreases
the evaporation rate of the tear film and improves the healing
mechanisms of the cornea [18–21]. The generally applied
concentration of HA in artificial tear is 0.1–0.5%w/w. In our
6 Journal of Ophthalmology
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Figure 5: (a) Adhesive force and (b) work of adhesion of ThioPASP-DME solutions under (◻) blank, (◼) in vitro, and (󳵳) ex vivo conditions
as functions of the polymer modification (∗𝑝 ≤ 0.05, significant difference from the blank; and ∗∗∗𝑝 ≤ 0.001, highly significant difference
from the blank).
work, mucoadhesion of 0.5 and 1.0%w/w HA solutions on
porcine conjunctiva was measured and compared with that
of 10%ThioPASP-DME 10 solution.
Under ex vivo condition, the ThioPASP-DME 10 dis-
played significantly higher mucoadhesivity compared with
that of HAs (Figure 6).This phenomenon can be explained by
the structure of the new cationic polymer. The elevated work
of adhesion value may indicate the formation of disulfide
bond and ionic interactions between the polymer chains and
the ocular surface, while the viscosity of the polymer solution
remained at a moderate level. Complex viscosity of the 0.5%
HA, 1.0%w/w HA, and ThioPASP-DME solutions (at 10Hz)
were 80, 1680, and 580mPas, respectively. Increase of the
HA concentration from 0.5 to 1.0 did not affect the work of
adhesion.
4. Discussion
DED is a multifunctional disease involving the tears and
the ocular surface, associated with an increased osmolality
of the tear film and inflammation of the ocular surface.
The two most common causes of DED are insufficient tear
production and excessive tear evaporation, both of which
lead to hyperosmolality, ocular damage, or discomfort [3, 22].
Environmental factors (such as air dryness, pollution, or
working close to a computermonitor)may increase a tear film
dysfunction and cause further evaporative dry eye [23].
Because of the multifactorial pathology of DED, the
therapy tends to be very varied. In the main treatments,
artificial tears are used, especially preservative-free products,
but unfortunately these provide only palliative therapy. In
the event of inflammation, artificial tears are combined
with oral omega-3 supplements, mucin secretagogues, short-
term steroids, and daily cyclosporine A. When the DED is
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Figure 6: Work of adhesion of polymer solutions under ex vivo
conditions (∗∗∗𝑝 ≤ 0.001, highly significant difference from 0.5%
and 1.0%w/w HA).
more severe, autologous serum, oral tetracyclines, prosthetic
lenses, and systemic immune-suppressants are administered
[2, 3]. Locally applied eye drops are used several times
per day, which can cause toxic side effects because of the
preservative (especially benzalkonium chloride) present in
the formulations. These preservatives are cytotoxic to the
ocular surface by modifying the lipid phase of the tear film
[19].
Osmolality has been deeply investigated in DED and is
considered to be a very important factor. The osmolality of
the tears in a normal eye is 310 to 334mOsmL−1, but in
DED the osmolality is higher. One aim of artificial tears is to
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counter this hyperosmolality, but the effect is generally only
temporary. The osmolality of artificial tears is usually in the
interval from 181 to 354mOsmol L−1 [24, 25].
In the treatment of DED, stabilization of the tear film is
also very important. The tear film is stable for only a short
time, because it ruptures in consequence of the concentration
gradients and dispersion forces on the mucus layer. The
rupture results in the loss of moisturization of the cornea,
so that dry spots are formed, which irritate the corneal
nerve endings and induce blinking. Thanks to the eyelid
movements, a new tear film spreads over the eye surface.
The dispersion forces, the interfacial tension, and the viscous
resistance of the mucus layer affect the duration of rupture of
the mucin layer and the breakup time of the tear film [4].
When all of these factors are taken into consideration, it
appears clear that most of the physicochemical properties of
the optimum eye drop formulation must be similar to those
of the tear film and it must be hypoosmotic to balance the
hyperosmotic tears in DED.
In thiswork, we synthetized and characterizedThioPASP-
DME, cationic thiolated polyaspartamide bearing both
cationic tertiary amine and redox-responsive thiol pen-
dant groups, as a potentially mucoadhesive and tear film-
stabilizing excipient in the therapy of DED. The aim was the
synthesis of a mucin analogue polymer which can interact
with the ocular mucin via disulphide linkages and the ionic
interactions between the positively charged polymer and the
negatively chargedmucosal surface.Thanks to these complex
interactions, a continuous polymer network is formed on the
surface, thereby preserving the tear film with maintenance
of the hydration of the ocular surface. We assume that
ThioPASP-DME polymers can function as ophthalmic drug
demulcents, defined in US Food and Drug Administration
(FDA) monograph 21 CFR 349 as water-soluble polymers
applied topically to protect and lubricate mucous membrane
surfaces and to temper dryness and irritation.
We first investigated the physiological acceptability of our
formulations. Eye lubricants are recommended to be neutral
or slightly alkaline. The pH of the ThioPASP-DME polymer
solutions (pH = 8.7–8.8) was higher than that of normal
tears (pH = 7.4) and could be therefore adjusted by using
hydrochloric acid.
The polymer solutions (10%w/w) were hypoosmotic (87–
90mOsmol L−1) allowing the addition of other components,
which is favourable in the therapy of DED.The neutralization
process resulted in lower pH but higher osmolality (183.67
± 1.25mOsmol L−1), which is in the range of the osmolality
of artificial tears (from 181 to 354mOsmol L−1) [24, 25],
but this also allows the inclusion of further additives to
the formulation. Ocular lubricants utilized in DED usually
contain electrolytes (e.g., bicarbonate, potassium, and other
electrolytes), surfactants, and various types of viscosity-
increasing agents [26, 27].
Optical tests were performed in order to determine
the degree of visual disturbance caused by these polymer
solutions. The transmittance of the polymer solutions is
slightly modified over a broad range of the visible spectrum
and their refractive indices approximate to that of the tears.
Thus, they do not greatly affect the quality of vision, while in
addition they have a partial UV-filtering effect, which can be
favourable in ophthalmic therapy.
The polymer solutions can readily spread on the sim-
ulated eye surface, as indicated by the low contact angles.
This means that the formulations have the ability to establish
strong interactions with the surface and to resist elimination
immediately after administration.
TheThioPASP polymers are redox-sensitive and undergo
gelling in response to oxidative stress or agents [9]. The
present work revealed that the solutions of the ThioPASP-
DME polymers did not form gels in response to an oxidative
effect. This behaviour can be advantageous, because a sticky
feeling and a foreign body sensation can be avoided and
the swelling gel does not cause dehydration. On the other
hand, ThioPASP-DME interacts with mucin, as indicated
by the elevated 𝐺󸀠 in rheological experiments, with the
polymer therefore remaining on the surface without causing
a noteworthy increase in viscosity.
Tensile tests likewise verified the good adhesion of the
polymer solution to the ocular surface. Besides hydrogen
bonds, thiolated polymers are able to form covalent bonds
with the cysteine-rich subdomains of mucin. We addition-
ally immobilized other side groups with cationic, positively
charged groups, so that ionic interactions can also occur
[4]. Changes in the degree of thiolation did not affect the
adhesion appreciably, but an increased degree of thiolation
is not recommended because a higher number of thiol
side groups may result in lower stability of the polymers
against atmospheric oxidation during storage. Oxidation
during storage may lead to a lower dissolution rate prior to
application.The strongest adhesion was measured on excised
porcine conjunctiva, which suggests that not only do the
mucin-polymer interactions (disulphide bonds) play a role
in the adherence, but other secondary interactions may also
develop, improving the efficacy of the formulation.
ThioPASP-DME polymers showed better mucoadhesion
compared with conventionally used HAs in DED, while the
viscosity of their solution was not elevated.
5. Conclusion
We successfully adjusted the properties of ThioPASP-DME
(pH and osmolality) to the desired physiological levels
thereby resulting in a possibility to decrease side effects such
as irritation and dehydration. In consequence of their similar
structure to that of mucin, ThioPASP-DME solutions also
have the ability to stabilize the tear film. They can interact
with the ocular mucin and provide strong adhesion, ensuring
an improved residence time and prolonged hydration of the
ocular surface. Further beneficial properties of the polymer
solutions, such as good spreading on the ocular surface,
marked transmittance, and a partial UV-filtering effect, can
provide new possibilities in the therapy of DED.
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